



EQUASENS

ADD

Software

GILBERT
DUPONT

GROUPE SOCIETE GENERALE

EPS 12/24e \downarrow -3.9% € 2.75 vs € 2.86 • EPS 12/25e \downarrow -3.8% € 2.94 vs € 3.06

PRICE*
€ 50.00
*closing 07/11/24

TP
€ 53.0
vs € 54.0

POTENTIAL
+6.0%

No organic rebound expected in Q4

Equasens failed to get back to organic growth in Q3 (-3.4%). This performance falls short of our scenario for a return to growth. We have lowered our estimates. Add rating confirmed. New TP of €53.

9 months sales + Contact

Bloomberg EQS FP
Market cap. €m 759
Free Float €m 246
Volume (3M) €m 0.32/day



PERFORMANCE	1M	6M	12M
Absolute	-4.6%	-15.0%	-27.5%
Rel. / CAC M&S	-3.5%	-5.8%	-30.9%

AGENDA

06/02/2025 (after Mkt): 2024 Sales

FINANCIAL ANALYST(S)



Gabriel Santier
+33 (0) 1 40 22 41 53
gabriel.santier@socgen.com

Document completed on 08/11/2024 - 09:30

Document published on 08/11/2024 - 09:31

Q3 sales of €50.2m (-3.4% org.) vs. GD €55.0m (+7.6% org.)

Equasens has reported Q3 sales of €50.2m, underlying organic growth of -3.4%. The impact of recent acquisitions represented some €2m in Q3. This performance falls short of our forecast for €55m (+7.6% org.). In all, 9M sales come out at €158.2m (-6.1% org.).

No return to growth for the Pharmagest division (76% of Q3 sales, -1.6%)

Despite the improved trend in the Group's main division, Pharmagest (76% of Q3 sales), which came out slightly ahead in Q3 (+3.2% on a reported basis), its second division, Axigate Link (14% of sales), weighed heavily on Q3. Software solutions for nursing homes fell by -3% to €7.2m. In the Pharmagest division, sales in France were flat (+0.9%), while the rest of Europe remained upbeat at +24% (gain in market share in Italy combined with the acquisition in Germany).

Management confident for Q4. GD scenario lowered: EPS -4%

Despite a disappointing organic performance, management has reiterated its target of a return to growth in H2, inferring a clear rebound in Q4. In view of this publication, which falls short of our expectations, we have lowered our overly aggressive FY top line guidance. We now expect 2024 sales of €220.2m, down -2.8% on an organic basis vs. +1%, i.e. Q4 sales of €62m (+6.8% on an organic basis). Our EBIT is automatically down to €49.9m, and we expect the EBIT margin to fall by -2.7 pts to 22.7%. Overall, our 2024/2025 EPS sequence is down by around -4% on average.

FactSet consensus on 07/11/2024 (3 analysts, including GD) 2024

Sales: €222.4m (+1.2% on a reported basis);
EBIT: €47.8m, giving an EBIT margin of 21.5%;
Net attributable income: €40.7m

Add rating confirmed. TP of €53 (DCF)

In our view, a return to sustainable double-digit organic growth remains the major catalyst for the share price, but this is by no means a given (GD 2025e sales: +6.5% / consensus: +7.7%). As a result, we are maintaining our Add rating on this share. After updating our model, our TP comes out at €53 (DCF) vs. €54.

STOCK RATIOS	12/23	12/24e	12/25e	12/26e
P/E	19.7x	18.2x	17.0x	15.3x
PEG	15.4x	ns	2.5x	1.4x
P/CF	15.0x	12.9x	12.3x	11.4x
EV/Sales	5.0x	3.3x	3.0x	2.7x
EV/EBITDA	15.9x	11.0x	10.1x	8.9x
EV/C. EBIT	19.6x	14.5x	13.1x	11.2x
EV/EBIT	19.6x	14.5x	13.1x	11.2x
EV/Capital employed	5.2x	3.2x	3.1x	3.0x
P/BV	4.1x	3.0x	2.7x	2.5x
FCF yield	4.8%	5.9%	6.2%	7.0%
Yield	2.0%	2.7%	2.9%	3.1%

FINANCIAL DATA	12/23	12/24e	12/25e	12/26e
Sales (€m)	219.7	220.2	234.5	247.5
C. EBIT (€m)	55.8	49.9	53.6	60.1
C. EBIT/Sales	25.4%	22.7%	22.9%	24.3%
EBIT (€m)	55.8	49.9	53.6	60.1
Net attributable profit (€m)	47.0	41.8	44.6	49.6
Adjusted EPS (€)	3.10	2.75	2.94	3.27
Chg.	1.3%	-11.0%	6.7%	11.2%
FCF (€m)	53.4	44.7	47.1	52.8
Net fin. debt (€m)	-22.7	-33.4	-60.0	-90.9
Gearing	-9.9%	-13.2%	-21.6%	-29.7%
ROCE	21.9%	17.0%	18.2%	20.5%

PRICE*
€ 50.00
*closing 07/11/24

TP
€ 53.0
vs € 54.0

POTENTIAL
+6.0%

Activity

€crBusiness software solutions for
professionals and healthcare
establishments

Market data

12M Low/High € 45.10/€ 69.10
Volume (3M) 6,536 shares/day
Number of shares 15,174,125
Market cap. €m 759
Free Float €m 246
Market Euronext A
Sector Software
Bloomberg EQS FP
Isin FR0012882389
Index CAC SMALL

Shareholders on 31/12/23



Marque Verte Santé 60.5%
Free float 32.4%
Coopérative Welcoop 6.1%
Treasury shares 0.9%

Employees on 31/12/23

1,288

2023 sales by quarter

Q4 26%
Q2 26%
Q1 26%
Q3 23%

2023 sales by business unit**Sales and C. EBIT Margin**

PROFIT LOSS STATEMENT (€m)	12/21	12/22	12/23	12/24e	12/25e	12/26e
Sales	193.1	214.1	219.7	220.2	234.5	247.5
Chg.	12.4%	10.9%	2.6%	0.2%	6.5%	5.5%
Chg. lfl	12.4%	8.8%	1.3%	-2.8%	6.5%	5.5%
EBITDA	62.7	70.3	68.7	65.9	69.7	75.8
C. EBIT	50.3	55.2	55.8	49.9	53.6	60.1
EBIT	50.3	55.2	55.8	49.9	53.6	60.1
Net interest income	1.6	-0.8	1.7	4.7	4.7	4.7
Tax	-10.6	-6.2	-9.9	-12.8	-13.7	-15.2
Income from associates	-0.1	0.4	1.3	1.0	1.0	1.0
Net earnings from discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0
Minority interests	-2.0	-2.2	-1.9	-1.0	-1.0	-1.0
Net attributable profit	41.2	46.4	47.0	41.8	44.6	49.6
Adjusted net attr. profit	41.2	46.4	47.0	41.8	44.6	49.6

CASH FLOW STATEMENT (€m)	12/21	12/22	12/23	12/24e	12/25e	12/26e
Cash Flow	53.1	34.6	62.4	56.7	60.2	64.8
- Chg. in WCR	-5.5	22.4	5.6	1.6	1.7	3.0
- Capex	10.3	10.1	14.5	13.6	14.8	15.0
= Free Cash Flow	37.2	46.9	53.4	44.7	47.1	52.8
- Net financial investment	-25.9	-8.3	-2.0	-15.0	0.0	0.0
- Dividends	-15.0	-16.5	-17.5	-19.0	-20.5	-21.9
+ Capital increase/Share buybacks	-5.5	-1.2	0.0	0.0	0.0	0.0
+ Others	0.0	0.0	0.0	0.0	0.0	0.0
= Chg. net financial debt	6.7	-20.8	-21.5	-10.7	-26.6	-31.0

BALANCE SHEET (€m)	12/21	12/22	12/23	12/24e	12/25e	12/26e
Goodwill	83.7	83.1	83.7	96.7	95.2	93.7
Other intangible assets	123.2	121.5	125.7	140.8	141.7	142.0
Tangible assets	27.7	26.6	22.7	21.3	20.1	20.1
Financial assets	56.9	65.5	67.5	67.5	67.5	67.5
WCR	-26.1	0.7	-5.3	-4.9	-4.7	-5.8
Shareholders' equity (group share)	159.0	189.8	219.3	242.1	266.2	293.9
Equity + minorities	165.2	196.8	228.2	252.0	277.2	305.9
Cash and equivalent	64.8	68.0	102.0	112.7	139.3	170.3
Net financial debt	19.6	-1.2	-22.7	-33.4	-60.0	-90.9
Net financial debt excluding IFRS 16	9.5	-11.1	-33.4	-44.1	-70.7	-101.6
Capital employed	181.6	214.3	210.6	224.7	224.6	223.8

PER SHARE DATA (€)	12/21	12/22	12/23	12/24e	12/25e	12/26e
Number of shares (000)	15,174	15,174	15,174	15,174	15,174	15,174
Number of diluted shares (000)	15,174	15,174	15,174	15,174	15,174	15,174
Adjusted EPS	2.71	3.06	3.10	2.75	2.94	3.27
Reported EPS	2.71	3.06	3.10	2.75	2.94	3.27
CF per share	3.15	4.00	4.07	3.87	4.06	4.37
Book value per share	10.89	12.97	15.04	16.61	18.27	20.16
Dividend	1.15	1.15	1.25	1.35	1.44	1.54
Payout	42%	38%	40%	49%	49%	47%

RATIOS	12/21	12/22	12/23	12/24e	12/25e	12/26e
Gross margin/Sales	80.9%	81.0%	80.5%	80.5%	80.5%	80.5%
EBITDA/Sales	32.5%	32.8%	31.3%	29.9%	29.7%	30.6%
C. EBIT/Sales	26.0%	25.8%	25.4%	22.7%	22.9%	24.3%
EBIT/Sales	26.0%	25.8%	25.4%	22.7%	22.9%	24.3%
Corp. tax rate	20.5%	11.4%	17.2%	23.5%	23.5%	23.5%
Adjusted NR/Sales	21.3%	22.7%	22.2%	19.4%	19.4%	20.4%
Capex/Sales	5.4%	4.7%	6.6%	6.2%	6.3%	6.1%
Capex/D&A	0.8x	0.7x	1.1x	0.9x	0.9x	1.0x
FCF/Sales	19.3%	21.9%	24.3%	20.3%	20.1%	21.3%
FCF/EBITDA	59.3%	66.7%	77.8%	67.8%	67.6%	69.6%
Goodwill/Equity + minorities	50.7%	42.2%	36.7%	38.4%	34.3%	30.6%
WCR/Sales	-13.5%	0.3%	-2.4%	-2.2%	-2.0%	-2.3%
Gearing	11.9%	-0.6%	-9.9%	-13.2%	-21.6%	-29.7%
Net financial debt/EBITDA	0.3x	0.0x	-0.3x	-0.5x	-0.9x	-1.2x
EBITDA/Financial charges	ns	85.0x	ns	ns	ns	ns
ROCE	22.0%	22.8%	21.9%	17.0%	18.2%	20.5%
ROE	24.9%	24.7%	21.4%	17.0%	16.5%	16.5%

STOCK MARKET DATA	12/21	12/22	12/23	12/24e	12/25e	12/26e
Share price performance	-15.6%	-20.5%	-18.2%	-18.2%	-	-
Share price performance vs. CAC M&S	-27.6%	-7.7%	-19.4%	-15.3%	-	-
Share price High (€)	122.60	92.70	85.00	66.90	-	-
Share price Low (€)	83.60	58.60	56.40	45.10	-	-
Enterprise value (€m)	1,507.4	1,170.1	1,090.5	724.2	702.3	675.7
= Market cap.	1,468.5	1,174.9	1,115.4	758.7	758.7	758.7
+ Net financial debt	19.6	-1.2	-22.7	-33.4	-60.0	-90.9
+ Minorities	6.2	7.0	8.9	9.9	10.9	11.9
+ Provisions & others	70.0	54.9	56.4	56.5	60.1	63.5
- Financial assets	56.9	65.5	67.5	67.5	67.5	67.5

VALUATION	12/21	12/22	12/23	12/24e	12/25e	12/26e
P/E	34.7x	24.4x	19.7x	18.2x	17.0x	15.3x
PEG	1.0x	1.9x	15.4x	ns	2.5x	1.4x
P/CF	29.9x	18.7x	15.0x	12.9x	12.3x	11.4x
EV/Sales	7.8x	5.5x	5.0x	3.3x	3.0x	2.7x
EV/EBITDA	24.0x	16.7x	15.9x	11.0x	10.1x	8.9x
EV/C. EBIT	30.0x	21.2x	19.6x	14.5x	13.1x	11.2x
EV/EBIT	30.0x	21.2x	19.6x	14.5x	13.1x	11.2x
EV/Capital employed	8.3x	5.5x	5.2x	3.2x	3.1x	3.0x
P/BV	8.6x	5.8x	4.1x	3.0x	2.7x	2.5x
FCF yield	2.5%	4.0%	4.8%	5.9%	6.2%	7.0%
Yield	1.2%	1.5%	2.0%	2.7%	2.9%	3.1%

DISCLAIMER

The brokerage firm Gilbert Dupont is authorised by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) as an investment services provider and subject to its supervision.

The brokerage firm Gilbert Dupont is also regulated by the AMF in respect of the investment services it is authorised to conduct.


Please note that Gilbert Dupont does not maintain a permanent place of business in the United Kingdom and is not authorised by the UK Prudential Regulation Authority or the Financial Conduct Authority. Customers of Gilbert Dupont are not eligible for either the UK Financial Services Compensation Scheme or the Financial Ombudsman Service and monies placed with Gilbert Dupont do not benefit for depositor protection under the UK deposit protection regime. If you would like further information on the protections applicable to our services as a French authorised and regulated investment firm, please contact your usual contact within Gilbert Dupont.

The information, estimates and comments contained in this document are based on sources we consider to be reliable, although their accuracy cannot be guaranteed. They reflect our opinion at the date of publication and can be modified without prior warning. Our stock market opinions are brought up to date on a continual basis. Any change in opinion is accompanied by a written comment. Our Target prices are derived via different methods which are weighted (DCF, Comparable quoted stock market values, Sum of the parts, NAV, Transaction Multiples,...).

Reference prices are based on closing prices. This information is legally protected under the provisions of intellectual property law. Accordingly, the said information may not be used or duplicated without prior authorization. The PEA SME logo associated with all stocks that are eligible for the French PEA SME savings scheme is provided for information purposes only and the brokerage firm Gilbert Dupont cannot be held responsible for any errors or omissions in the communication of this logo. Opinion changes from the past 12 months and all regulatory disclosures can be found by clicking the "Conform" tab at the bottom right of the front page of our website: www.gilbertdupont.fr.

STOCK OPINIONS:

Given on a 6 to 12-month horizon, these are established by the financial analysts. These ratings are formulated using a general framework outlined below as well as non-quantitative factors (news-flow, momentum, share price volatility, etc).



Price Target : This is derived via different methods which are weighted (DCF, comparable quoted stock market values, Sum of the parts, NAV, transaction multiples).

- Buy : potential increase of more than 15%
- Add : potential increase of between 5 and 15%
- Reduce : potential between -5% et +5%
- Hold : opinion possible in case of IPO
- Bring to the offer : recommandation used as applicable when a compagny is the subject of a takeover bid
- Sell : potential drop of more than -5%
- Under Review : temporarily when a special event occurs

Favorite stocks : 2 exisiting lists, each one with a maximum of 10 companies

- Midcaps List : Mkt cap. > €m350 the day of entry
- Smallcaps List : Mkt Cap. < €m350 the day of entry

Calculation of absolute and relative performance is done on the opening price of the day on entry or exit from the list

DISCLOSURES

1. Gilbert Dupont acts as the Company's Liquidity Provider.
2. Gilbert Dupont has entered into a service agreement with the Company.
3. Gilbert Dupont has entered into a service agreement with the Company that includes a sponsored research commitment.
4. Research partially paid for by the issuer, for a reserved distribution, performed in accordance with the Charter on Sponsored Research.
5. Research paid in full by the issuer, for a public distribution, performed in accordance with the Charter on Sponsored Research.
6. This document is produced in accordance with the provisions of the Best Practice Charter relating to Sponsored Research signed by AMAFI, AFG and SFAF, in consultation with the AMF, on May 11th 2022.
7. This document is produced in accordance with the provisions of the Best Practice Charter relating to Sponsored Research signed by AMAFI, AFG and SFAF, in consultation with the AMF, on May 11th 2022.
8. Gilbert Dupont is Listing Sponsor
9. Gilbert Dupont has a share buy-back agreement with the Company.
10. Gilbert Dupont handled the placement of the company's share issuance on Euronext Growth.
11. Gilbert Dupont is responsible for a placement of the Company's securities.
12. Gilbert Dupont has participated in a placement of the Company's securities during the last 12 months
13. The revenues received by Gilbert Dupont from the various contracts linking it to the Company represent more than 5% of the consolidated gross revenues of Gilbert Dupont for the previous financial year.
14. The revenues received by the external service provider responsible for drafting this document and any other of its revenues related to the Company represent more than 5% of its consolidated gross revenues for the previous financial year.
15. Gilbert Dupont has, in a temporary capacity, a net short position of more than 0.5% of the capital of the issuer
16. Gilbert Dupont has, in a temporary capacity, a net long position of more than 0.5% of the capital of the issuer.
17. This document has been sent to the company for review before it is published. This rereading didn't prompted the analyst to adjust his target price and his stock market recommendation
18. This document was sent to the company for a rereading prior to its publication. This rereading prompted the analyst to adjust his target price and his stock market recommendation
19. The stock has been the subject of a Public Offer presented by Société Générale in the last 12 months.

COMPANY	DISCLOSURES APPLICABLES
Equasens	1,3,4,6

HISTORICAL TARGET PRICE (12M)				HISTORICAL CHANGE OF OPINION (12M)			
Company	Date	Price (€)	TP (€)	Company	Date	Previous	Current
Equasens	08/11/24	50.00	53.0	Equasens	10/11/23	Buy	Add
Equasens	10/07/24	49.55	54.0				
Equasens	13/05/24	55.80	58.0				
Equasens	07/02/24	48.30	59.0				
Equasens	23/01/24	58.70	65.0				
Equasens	10/11/23	56.40	78.0				

VALUATION METHODOLOGY

DCF (53€, wacc : 9,4 %, LT EBIT margin: 25,5 %, LT growth rate: 1,5 %)

RISK(S)

Decrease in the number of pharmacies and already high equipment ratios